-
Uncategorized1 day ago
Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act
The star of the licensing agreement, a small-molecule gamma-secretase modulator, will help buff Eli Lilly’s position in Alzheimer’s disease, currently headlined by its anti-amyloid antibody Kisunla.
-
Uncategorized1 day ago
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
Improved survival on display at the American Society of Clinical Oncology (ASCO) in Chicago; Pfizer’s unusual pact with China’s Innovent highlights a new type of collaboration;...
-
Uncategorized2 days agoOpinion: Even in abortion-protecting states, teens face unnecessary barriers to care
On May 28 the Nevada Supreme Court made the unanimous decision of halting enforcement of the state’s abortion parental notification law, allowing teens to access abortion...
-
Uncategorized2 days agoSTAT+: As the U.S. looks on, European countries feel growing pressure on drug prices
LONDON — In Europe, two divergent paths are emerging as countries grapple with what to do about drug prices, affecting pharma companies and patients across the...
-
Uncategorized2 days ago
Local trade groups must support life sciences in these difficult times
As the industry faces policy changes and significant cuts to federal funding, local ecosystems can bolster companies through innovative resources to sustain growth and keep the...
-
Uncategorized2 days ago
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity
Over the past decade, Eli Lilly has bought out more biotechs than any of the other top 12 pharmas by revenue—with 10 of those acquisitions arriving...
-
Uncategorized2 days ago
T-Cell Synapse Formation Is Restrained by PTPN22–PSTPIP1 Signaling
T cells don’t simply switch on—they reshape themselves. When these immune sentinels recognize a target, they rapidly reorganize their internal scaffolding to build an immunological synapse,...
-
Uncategorized2 days ago
Biotech’s coming of age
Nature Biotechnology, Published online: 10 June 2026; doi:10.1038/s41587-026-03179-0 Biotech is back. But continued investor caution, the rise of China and fast-moving AI are changing the sector’s...
-
Uncategorized2 days agoSTAT+: The shortage of many medicines in the U.S. remains a ‘systemic’ problem, a new analysis finds
The number of prescription drug shortages in the U.S. fell by 23% last year, marking the second consecutive year of declines and the lowest level since...
-
Uncategorized2 days ago
Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs
Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
